Effect of Pomegranate Seed Powder on Markers of Metabolic Syndrome

July 10, 2023 updated by: Asif Ali

Therapeutic Effects of Pomegranate Seed Powder on Metabolic Syndrome Markers

Metabolic syndrome is a public health concern worldwide and in Pakistan as well. Abdominal obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low HDL cholesterol are its hallmarks while pomegranate seed's unique chemical composition has sparked research into the health benefits in same arena as weight control, blood lipid profile changes, and other metabolic disturbances. It's high time to study therapeutic efficiency of Pomegranate seed powder against metabolic syndrome.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Metabolic syndrome, accumulation of certain metabolic risk factors, such as abdominal obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low HDL cholesterol, has been noted as one of the most important risk factors for the epidemic of type 2 diabetes and cardiovascular disease in the 21st century. It has become a significant public health concern and a global epidemic with a prevalence rate of about 25% among American adults. Multiple researches have demonstrated the effectiveness of pomegranate in the management of diabetes, inflammatory conditions, obesity, and blood lipid levels, and consequently metabolic syndrome. Various pomegranate components have the potential to substitute anti-diabetic medications as well Pomegranate seed's unique chemical composition has sparked research into the health benefits, such as weight control, blood lipid profile changes, and other metabolic disorders.

seed powder can influence the patient's metabolic syndrome-related indicators.

Hypothesis:

Pomegranate seed powder can be effective to treat the individuals with impaired metabolism.

Methodology:

In a clinical trial, patients of metabolic syndrome (n=50) will be given pomegranate seed powder dose for over 8 weeks, twice a day. Biochemical outcomes including blood pressure, FBG, cholesterol, hemoglobin level will be determined before and after the completion of trial in addition to patient's weight. Finally, using one-way ANOVA and T-test, collected data will be analyzed.

Expected outcome: The study will explore the potential of pomegranate seed powder in treating metabolic syndrome's risk factors. Therefore, our findings on the studied parameters of patient will assist future researchers in developing tested, evidence-based recommendations.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Pakistan
    • Punjab
      • Lahore, Punjab, Pakistan, 54000
        • Recruiting
        • University of Veterinary and Animal Sciences Lahore
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • BMI > 25kg/m2
  • Dyslipidemia
  • Altered blood glucose level
  • Age 30-55 ( male and female)

Exclusion Criteria:

  • Thyroid disorder
  • Liver disease
  • Kidney disorder
  • Cancer etc

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Metabolic syndrome Patients
Pomegranate seed powder is administered for alleviating symptoms of metabolic syndrome
Dietary supplement: Pomegranate seed powder
10 g powder / day
Other Names:
  • Punica granatum

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lipid Profile
Time Frame: 7 weeks
The change in Lipid Profile, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.
7 weeks
Fasting Glucose
Time Frame: 7 weeks
The change in Blood Glucose level, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.
7 weeks
Blood Pressure
Time Frame: 7 weeks
The change in both systolic and diastolic blood pressure after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.
7 weeks
Weight
Time Frame: 7 weeks
The change in weight, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.
7 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asif Ali

Investigators

  • Study Director: Dr. Asif Ali, Mphil, University of Veterinary and Animal Sciences Lahore

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2023

Primary Completion (Estimated)

July 20, 2023

Study Completion (Estimated)

August 24, 2023

Study Registration Dates

First Submitted

April 11, 2023

First Submitted That Met QC Criteria

July 10, 2023

First Posted (Actual)

July 13, 2023

Study Record Updates

Last Update Posted (Actual)

July 13, 2023

Last Update Submitted That Met QC Criteria

July 10, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UVAS (Other Identifier: UNIVERSITY OF VETERINARY & ANIMAL SCIENCES, LAHORE)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Intervention study, data will be confidential to maintain patients privacy, enrollment of patients with their consent

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe